Analytical Data
-
Gene name
HCP5
- Application
-
Alternative Names
HCP5; HLA class I histocompatibility antigen protein P5; HLA complex protein P5; Protein P5-1
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q6MZN7
-
Expression Region
3-103aa
-
AA Sequence
LRMSEHRNEALGNYLEMRLKSSFLRGLGSWKSNPLRLGGWTILLTLTMGQGEPGGPQGDPWVPHELLLPSLCDSSHASSWGSGSITCAWRGGDSSSHPLVS
-
Molecular Weight
36.85 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HCP5, or Human Cytomegalovirus Protein 5, is a protein of considerable interest in virology and immunology due to its potential role in the pathogenesis of human cytomegalovirus (HCMV) infections. HCMV is a widespread pathogen that can lead to severe complications in immunocompromised individuals, such as transplant recipients and HIV patients, as well as contributing to congenital infections in newborns. Understanding the structure and function of HCP5 is crucial to elucidate how HCMV evades the host immune response. Additionally, recombinant HCP5 proteins are being explored as potential candidates for vaccine development, aimed at eliciting a robust immune response that could provide protection against HCMV. Research in this area focuses on the characterization of HCP5's interaction with host cellular mechanisms, its role in modulating immune responses, and the development of recombinant versions for use in diagnostics and therapeutics. Overall, studying HCP5 represents a significant step toward developing effective interventions against HCMV and mitigating the associated health risks.











